Clinical trials: DCIS
Breast Cancer
Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of simvastatin may keep cancer from coming back in women who are at high risk for a new breast cancer after…
- Trial name
- NCT00334542
- Testing
- simvastatin
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Carcinoma, Ductal Breast Carcinoma In Situ
Oxybutynin Chloride in Managing Hot Flashes
This randomized phase III trial studies how well oxybutynin chloride works in managing hot flashes in patients who are not candidates for, or not interested in hormone replacement therapy.
- Conditions
- Breast Carcinoma, Ductal Breast Carcinoma In Situ, Hot Flashes, Lobular Breast Carcinoma In Situ
- Trial name
- NCT02961790
- Testing
- Oxybutynin Chloride, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Academic and Community Cancer Research United
Breast Cancer
Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using either tamoxifen or anastrozole may fight breast cancer by blocking the use of estrogen.
- Trial name
- IBIS-II DCIS (NCT00072462)
- Testing
- tamoxifen citrate, Anastrozole
- Where
- 97 sites in Australia, Austria and 12 more
- Volunteers
- 2,980 people
- Sponsor
- Queen Mary University of London
Breast Cancer, Fatigue
Three Different Programs of Paced Breathing in Treating Hot Flashes in Women
RATIONALE: Paced breathing may be an effective way to reduce the number and severity of hot flashes in women who have survived breast cancer.
- Conditions
- Breast Cancer, Fatigue, Hot Flashes, Sleep Disorders
- Trial name
- NCT00569166
- Testing
- Paced breathing (15 min once daily, 6 breaths/min), Paced breathing (15 min twice daily, 6 breaths/min), Paced breathing (10 min once daily, 14 breaths/min)
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Mayo Clinic
Breast Cancer
Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the…
- Trial name
- NCT00290745
- Testing
- letrozole, tamoxifen citrate, conventional surgery
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- University of California, San Francisco
Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
RATIONALE: Zoledronic acid may prevent bone loss and help prevent or lessen musculoskeletal symptoms in women receiving hormone therapy for breast cancer.
- Conditions
- Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer
- Trial name
- NCT01194440
- Testing
- letrozole, zoledronic acid
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
This phase I trial studies the side effects and best dose of bexarotene in preventing breast cancer in patients at high risk for breast cancer.
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT03323658
- Testing
- Bexarotene, Questionnaire Administration
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Ductal Breast Carcinoma In Situ, HER2/Neu Positive
Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
This randomized phase I/II trial studies the side effects and best dose of lapatinib ditosylate and to see how well it works in treating patients with ductal breast carcinoma in situ.
- Trial name
- NCT00555152
- Testing
- Laboratory Biomarker Analysis, Lapatinib Ditosylate
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, LCIS
Tumor: Breast Ratio Study
This is an observational study of 3 arms: breast conservation therapy, mastectomy and reconstruction, and mastectomy only.
- Conditions
- Breast Cancer, LCIS, DCIS
- Trial name
- T:B (NCT02216136)
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Washington University School of Medicine
Breast Cancer
Radiation Therapy in Treating Patients With Recurrent Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. It is not yet known whether a single dose of radiation therapy is more effective than implant radiation therapy for 5 days in…
- Trial name
- NCT00945061
- Testing
- intracavitary balloon brachytherapy, intraoperative radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Carcinoma
A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)
The subjects in this trial have been diagnosed as having a pre-cancerous disease of the breast called ductal carcinoma in situ (DCIS). This condition is associated with the development of breast cancer in up to 50% of cases.
- Trial name
- NCT00183963
- Testing
- Tamoxifen, Fulvestrant
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Southern California
Female Breast Carcinoma, Female Ductal Carcinoma In Situ
A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant
This is an open-label, non-randomized pharmacokinetic study of fulvestrant in women scheduled for mastectomy or lumpectomy. Eligible subjects will be identified with breast cancer or DCIS.
- Trial name
- 007 (NCT02540330)
- Testing
- Fulvestrant
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Atossa Therapeutics, Inc.
Ductal Carcinoma In Situ
Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
Primary Objectives: To determine the effect of a single dose of Herceptin (trastuzumab) on the proliferation rate of Her-2/neu over-expressing ductal carcinoma in situ (DCIS) To evaluate the effect of a single dose of Herceptin…
- Trial name
- NCT00496808
- Testing
- Herceptin (Trastuzumab)
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Ductal Carcinoma in Situ
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor
This will be a proof of principle clinical trial to evaluate the use of pasireotide (SOM230) in women with ductal carcinoma in situ (DCIS) of the breast.
- Trial name
- NCT01372618
- Testing
- SOM 230 / Pasireotide
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health